- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period
This study looks at a new drug, SAR443820, for multiple sclerosis (MS). Researchers want to see if it lowers a marker in the blood called neurofilament, which can show nerve damage. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
For: Multiple sclerosisSpain · Belgium · Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1, open-label, single-center study to determine the absorption, distribution, metabolism, and excretion of a single oral dose of SAR443820 containing microtracer [14C]-SAR443820 in healthy male participants
This study is looking at how a new drug called SAR443820 moves through the body in healthy men. It aims to understand how the body absorbs, uses, and gets rid of the drug, which could one day help people with ALS.
For: amyotrophic lateral sclerosis (ALS)Netherlands